AI Safety Agent Shows Gains From Memory in Drug Trial Review Demo

TrialSleuth AI is an agent that reviews a new drug before its first human trial and draws on past results. In a demo, a made-up cancer drug called HLV-772 was reviewed first with memory switched off, producing a generic answer without specific evidence. With memory enabled, the same review flagged concrete risks tied to recalled past studies, including liver impairment, drug interactions, and dosing timing. A new heart-safety finding was then added to memory, and the next review included a heart-monitoring recommendation without any code or prompt changes. The app presents flagged risks for human experts rather than declaring a drug safe.
This is an AI-generated summary. ShortSingh links to the original source for the complete article.

Discussion (0)
Log in to join the discussion and vote.
Log in